Scand J Rheumatol. Nov-Dec;35(6):435-40.Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
Journal of Rheumatology; 32: 2116-2124. Anti- Tumor Necrosis Factor-α therapy augments Dipeptidyl Peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
Biological Research; 38: 7-12.Multiple imputation procedures allow the rescue of missing data: An application to determine serum tumor necrosis factor (TNF) concentration values during the treatment of rheumatoid arthritis patients with anti-TNF therapy.
J Immunol. Aug 1;173(3):1731-7. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells.
European Cytokine Network; 15 (4): 364-370.The –308 polymorphism in the promoter region of tumor necrosis factor-alpha (TNFα) gene and ex vivo lipopolysaccharide-induced TNFα expression in patients with aggressive periodontitis.
Rheumatology (Oxford) 2003; 42: 308-313.The –308 polymorphism in the tumor necrosis factor gene promoter region and ex - vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in chilean patients with rheumatoid arthritis.
Biological Research 2001; 34: 237-241.Genetic polymorphism at position –308 in the promoter region of the tumor necrosis factor (TNF): Implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population.